Anaheim Bio

Anaheim Bio is a preclinical-stage biotechnology company based in Leiden, the Netherlands, formed in 2026 from programs spun out of Alesta Therapeutics. Its lead program, ANA-1, is a small molecule inhibitor designed to lower extracellular PPi in the joint to limit calcium pyrophosphate crystal formation, aiming to become the first disease-modifying therapy for calcium pyrophosphate deposition disease (CPPD), an inflammatory arthritis affecting an estimated 4-7% of adults in Europe and the US that has no approved therapy targeting the underlying crystal deposits. The company is backed by Alesta's former investors, including Droia Ventures, Frazier Life Sciences, RTW Investments, Novartis Venture Fund, RV Invest and Thuja Capital.

  • Series A
  • Biotechnology
  • Clinical Trials
  • Pharmaceuticals
  • Healthcare & Life Sciences

1

Round

1

Industry

4

Tags

Nov 5, 2026

Latest raise

Funding activity · 1 round

Raise timeline

  1. Nov 5, 2026

    EUR 44.2M

    Series A

    • Droia Ventures
    • Frazier Life Sciences
    • RTW Investments
    • Thuja Capital
    • RV Invest
    • Novartis Venture Fund

    Article coming soon.

Pricing

Research Anaheim Bio — then scale the playbook

Public hubs orient you on the raise. Paid plans unlock live AI adoption signals across your market.

Enterprise

Custom pricing for unlimited scale. Let's talk.

Contact sales

Growth plan

For individuals and small teams getting started with AI buyer intelligence.

$149

/month

Features

  • Access to core AI adoption signals
  • 3–5 curated slices per week
  • 30–60 companies / week
  • AI Adoption Score
  • Deal-ready insights (why + pitch angle)
  • Basic filters (recency, slice, score)
  • CSV export
Most popular

Pro plan

For outbound teams and agencies that need more coverage and faster signal cadence.

$249

/month

Features

  • Everything in Growth, plus:
  • Full access to all slices
  • 60–120 companies / week
  • Higher-frequency signal updates
  • Priority / early signals (before Growth)
  • Advanced filters (industry, size, use case)
  • Deeper company insights
  • Faster export + bulk workflows

Act on this raise

See if Anaheim Bio is moving on AI

Funding is the starting point. VeilStrat shows whether capital is showing up as hiring, tools, and web activity you can sell into.

© 2026 VeilStrat. All rights reserved.All systems operational